Peptilogics is developing a new class of antibiotics to address the growing epidemic of drug resistant bacterial infections. Peptilogics’ approach has a novel mechanism of action that provides broad-spectrum antibacterial activity, and that makes the generation of resistance more difficult than occurs with traditional antibiotics.